NXG — Fluorescence In Situ Hybridization, Topoisomerase Ii Alpha, Gene Amplification And Deletion Class III

FDA Device Classification

FDA product code NXG covers "Fluorescence In Situ Hybridization, Topoisomerase Ii Alpha, Gene Amplification And Deletion", a Class III medical device. Submissions are reviewed by the Unknown panel.

Classification Details

Product Code
NXG
Device Class
Class III
Regulation Number
Submission Type
Review Panel
PA
Medical Specialty
Unknown
Implant
No

Definition

Topoisomerase ii alpha (top2a) fluorescence in situ hybridization (fish) kit is to detect the top2a gene copy number changes (amplification and deletion) in breast cancer using formalin-fixed, paraffin-embeded human breast cancer tissue specimen.